BP
LEGN icon

Ballentine Partners’s Legend Biotech LEGN Stock Holding History

Ballentine Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
+7,235
New +$195K ﹤0.01% 992

Other funds holding LEGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
AWM
Avior Wealth Management Omaha, Nebraska $3.8B AUM 23.28% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Ballentine Partners's LEGN Position: Q2 2026 in Review

Ballentine Partners opened a new position in Legend Biotech (LEGN) in Q2 2026: 7,235 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #992 among its holdings.

14 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Ballentine Partners held 7,235 shares of Legend Biotech worth $209K as of Q2 2026.
  • Legend Biotech was a new Ballentine Partners position in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #992 holding.
  • 14 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.